Navigation Links
Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell

ung's team set out to address two obstacles to gene therapy for pancreatic cancer: lack of a targeted gene expression system that hits the cancer hard but spares normal tissue, and the need for an animal model that allows monitoring of tumor growth and metastasis without having to kill and dissect the animal.

They solved the monitoring problem by modifying two lines of pancreatic cancer to stably express firefly luciferace enzyme - the bioluminescent agent that lights up fireflies. This allowed live imaging of the mice to monitor cancer progression.

The researchers already had developed several components of the gene expression system. Led by first author Xiaoming Xie, Ph.D., a postdoctoral fellow and now instructor in Hung's department, the team used those components and pieces developed elsewhere to painstakingly build what became C-VISA-BikDD.

They used a gene-based targeting promoter called CCKAR known to be active in pancreatic cancer but not in healthy pancreatic tissue. The problem with pancreatic-cancer-specific gene promoters such as CCKAR, Hung says, is that they select narrowly for cancer cells but are not highly active once they get there. The success of gene therapy depends on efficient gene expression after delivery.

A system using a viral promoter such as CMV has the opposite problem: strong activity but indiscriminate delivery of the therapeutic gene to healthy tissue, which increases toxicity. The team's goal was to retain CCKAR's selectivity while boosting its activity to levels seen in CMV promoter-driven therapy.

To strengthen activity, the team added two key components: a regulatory gene sequence known as WPRE and the two-step transcriptional amplification system (TSTA) known to amplify activity of the prostate-specific antigen (PSA) promoter.

This enhanced C-VISA package increased gene activity levels by 67.6 percent to 287 percent over the CMV-driven therapy in three lines of pancreatic cancer. Lab exp
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
5. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:7/31/2014)... , July 31, 2014  Today, Levi ... new extension to its PageCenterX ® content ... is designed to provide downtime reporting capabilities to ... LRS is releasing the product for general availability, ... EMR applications experience outages for a variety of ...
(Date:7/31/2014)... 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... quarter 2014, on Thursday, August 7, 2014 before markets ... webcast and conference call at 8:00 a.m. Eastern time ... host the call and webcast to discuss financial results ... accessed by calling (800) 708-4540 (domestic) or (847) 619-6397 ...
(Date:7/31/2014)... , July 31 2014  Northsight Capital, Inc. ... has been named Chairman and CEO of the company. ... management, legal matters, business development and investment banking. Mr. ... securities industry.  Before his career on Wall Street, Mr. ... of the U.S, Securities and Exchange Commission in ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Northsight Capital, Inc. Names Wall Street Veteran John Bluher, Former EVP And General Counsel Of Knight Trading Group, Chairman And CEO. 2
... PALO ALTO, Calif., May 3, 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: ... first quarter of 2011. Total revenues for ... to $35.2 million for the first quarter of 2010.  Total ... GAAP net income for the first quarter of 2011 ...
... 3, 2011 Coast Dental Services, Inc., announced today ... the assets of Dental Technology, Inc. (DTI), doing business ... licensed  health care service plan. DTI and its subsidiaries ... Texas, employing 1,200 staff members, including 130 dentists.  The ...
Cached Medicine Technology:Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 2Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 3Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 4Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 5Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 6Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 7Coast Dental to Acquire the Assets of SmileCare 2
(Date:7/31/2014)... OK (PRWEB) July 31, 2014 Shiitakes ... As in the recipe for Quick-Fix Spaghetti Sauce below, ... second-most consumed mushroom worldwide, valued for their deep flavor ... mushrooms. They absorb flavors of the foods they're cooked ... texture and offer high-protein, low-fat nutrition. Shiitakes are rich ...
(Date:7/31/2014)... San Francsico, CA (PRWEB) July 31, 2014 ... in Sweden have published the largest study ... from triage through either teledermoscopy or traditional letter ... indicate that smartphone referrals via patent pending iDoc24® ... of patients with skin cancer while potentially eliminating ...
(Date:7/31/2014)... -- A class of medications previously linked to ... negatively affect their physical functioning according to investigators ... Center for Aging Research, the University of East ... In a systemic review of more than a ... with anticholinergic properties, they report that these drugs ...
(Date:7/31/2014)... 31, 2014 Controlled application of vacuum pressure is ... brain injury (TBI), suggests an experimental study in the ... journal of the Congress of Neurological Surgeons . ... Wilkins , a part of Wolters Kluwer Health ... applied over the injured area of the brainshows promise ...
(Date:7/31/2014)... July 31, 2014 Rivetz Corp. today ... authentication services to cloud service providers. The combined solution ... protected multi-factor authentication with online systems. , There ... password-based authentication. It is the root cause of the ... around the globe. Instead of solving the problem, service ...
Breaking Medicine News(10 mins):Health News:Quick Fixin’ Summertime Meals with Shiitake Mushrooms -- Bring ‘em Home and Grow Your Own 2Health News:Quick Fixin’ Summertime Meals with Shiitake Mushrooms -- Bring ‘em Home and Grow Your Own 3Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 2Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 3Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 4Health News:Common drugs adversely impair older adults' physical as well as cognitive functioning 2Health News:Vacuum treatment may limit damage after traumatic brain injury 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3
... to meet with staff and patients and also to view the ... the opportune moment, the Prime Minister was targeted with questions about ... of the health service. ,To the volley of questions, ... will say it's the end of the NHS or, when you ...
... type 1 or juvenile-onset diabetes also works in a rat ... new report from researchers at Washington University School of Medicine ... 2 diabetes in the same way is very significant because ... prevalent than type 1 diabetes," says senior author Marc R. ...
... Rizal and Marikina City as of Thursday. // ... child from Balanga, Bataan were among its victims,According to ... Center the Valenzuela child was at “critical stage 4,” ... treatment Wednesday. ,Lustre stated that he was ...
... diseases that ails many millions of people in parts ... renewed thrust by The Bill & Melinda Gates Foundation, ... million. ,This fund will assist in controlling ... are spread by parasites and worms. These worms are ...
... Fiancée of England star Wayne Rooney, Coleen McLoughlin launched ... her desire to raise awareness of the work hospices ... much-needed funds.// ,Coleen, 20, has personal experience to ... disorder Rett Syndrome and is a regular visitor to ...
... issue of the British Medical Journal, calcium supplements to kids does ... ,According to the research, 90% of the maximum bone mass ... expected that enhancing bone mass at an early age might reduce ... results of 19 studies, on about 2,900 kids and teens aged ...
Cached Medicine News:Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 2Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 3
... supply is the latest edition ... offering. It sets new standards ... This product has unique features ... as microAmp detector, display and ...
... as a constant voltage power supply, the 105 ... and hilo range switch control the output, which ... 250 volts. One, two-position switch toggles the bright ... current. The 105 is equipped with an over ...
... power supply is capable of producing up to ... product operates in constant voltage or constant current ... crosses over from one mode of operation to ... A dual function, auto ranging 24-hour ...
... designed for horizontal and vertical gel electrophoresis ... accomplished. In this power supply model, output ... or constant voltage. Four sets of output ... simultaneously. This power supply's light, compact and ...
Medicine Products: